Centralized hub for advanced testing of nucleic
acids to simplify mRNA drug substance testing, accelerating
critical therapeutic development
TriLink BioTechnologies® (TriLink), a Maravai
LifeSciences company (NASDAQ: MRVI) and global provider of life
science reagents and services, has launched its Analytical Sciences
Center of Excellence (ASCE) hub. Expanding its comprehensive suite
of analytical testing capabilities, this new center of excellence
will minimize the delays and unexpected costs typically associated
with outsourced testing to multiple laboratories. This new center
of excellence will serve as the hub for all analytical innovation
and the Quality Control laboratories across the organization’s
manufacturing network.
Located within Maravai LifeSciences’s Pacific Center Boulevard
facility in San Diego’s Sorrento Valley, the ASCE will operate out
of a 4,000-square-foot lab equipped with advanced instrumentation
and support developers as they advance their drugs – starting with
plasmid DNA and continuing through mRNA manufacturing and
release.
“TriLink's new Analytical Sciences Center of Excellence will be
a transformative force in the development of nucleic acid
therapies,” shared Khaled Yamout, Senior Director of Analytical
Services at TriLink. “This new lab will allow us to expand our
analytical capabilities to meet the growing demands of the market,
including specific method development.”
Leaning on decades of technical expertise, TriLink continues to
lead the market with mRNA specific analytical services, having
developed and qualified 10 types of unique methods for the
characterization of mRNA covering 40 various constructs. With this
expansion, the center of excellence builds upon the organization’s
comprehensive method development for construct-specific assays with
new instrumentation to improve NMR, NGS, and LNP characterization.
The center of excellence will also be responsible for developing
cutting-edge analytical methodologies, including mRNA
fingerprinting and sequencing.
“We continue to witness exciting growth in nucleic acid
therapeutics – and rapid expansion calls for rapid innovation,”
added Kevin Lynch, TriLink’s VP and GM of GMP Operations. “The
ASCE’s centralized analytical capabilities and development of
analytical methodologies for the characterization of nucleic acids
will advance the industry as we continue to find ways to meet the
needs of developers working on life-saving therapeutics.”
In addition to the ASCE’s suite of analytical services, TriLink®
has a robust ® mRNA capping portfolio, advanced scale-up
capabilities, and unrivaled expertise in mRNA, oligonucleotide, and
plasmid production. Leveraging more than 25 years of experience,
TriLink® serves companies dedicated to advancing therapeutics,
vaccines, and diagnostics by delivering exceptional Contract
Development and Manufacturing Organization (CDMO) services.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is
helping to realize the power and potential of mRNA. As a global
leader in nucleic acid and mRNA solutions for more than 25 years,
TriLink delivers unrivaled chemical and biological experience, CDMO
services, and high-quality readymade and custom materials,
including its proprietary CleanCap® mRNA capping technology.
Pharmaceutical leaders, biotech disruptors and world governments
depend on TriLink to meet their greatest challenges, from
delivering the COVID-19 vaccine at warp speed, to empowering
innovative treatments in oncology, infectious diseases, cardiology,
and neurological disorders, to enabling future pandemic response
plans.
For more information about TriLink, visit
www.trilinkbiotech.com.
About Maravai
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
and novel vaccines. Maravai’s companies are leaders in providing
products and services in the fields of nucleic acid synthesis and
biologics safety testing to many of the world’s leading
biopharmaceutical, vaccine, diagnostics, and cell and gene therapy
companies.
For more information about Maravai LifeSciences, visit
www.maravai.com.
Forward-looking Statements
This press release contains, and Maravai’s officers and
representatives may from time-to-time make, “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995. Investors
are cautioned that statements in this press release which are not
strictly historical statements constitute forward-looking
statements, including, without limitation, statements regarding
cost- and time-savings of internal analytics testing; the extent
and benefit of Maravai’s expanded analytical testing capabilities
and Maravai’s ability to support quality control laboratories with
such capabilities; Maravai’s ability to attract and support
developers through each stage of development; the ASCE’s effect on
the development of nucleic acid therapies; Maravai’s expectations
for growth in demand of the development market; Maravai’s ability
to improve NMR, NGS and LNP characterizations; Maravai’s ability to
develop and successfully market new analytical methodologies,
including mRNA fingerprinting and sequencing; Maravai’s
expectations of continued growth in nucleic acid therapeutics; the
ASCE’s ability to advance the nucleic acid therapeutics industry
and meet the needs of the industry’s customers via the ASCE’s
analytical capabilities and development of analytical methodologies
for the characterization of nucleic acids; Maravai’s future
business capabilities; growth opportunities, including inorganic
growth; and future innovations, constitute forward-looking
statements and are identified by words like “believe,” “expect,”
“see,” “project,” “may,” “will,” “should,” “seek,” “anticipate,” or
“could” and similar expressions.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
management’s current beliefs, expectations and assumptions
regarding the future of Maravai’s business, future plans and
strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict
and many of which are outside of management’s control, as described
in more detail in the sections entitled “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in our most recent Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, as well as other documents
Maravai files with the Securities and Exchange Commission. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, and therefore you should not rely upon
them. These forward-looking statements reflect our current views
and we do not undertake to update any of these forward-looking
statements to reflect a change in its views or events or
circumstances that occur after the date hereof except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101202187/en/
Liz Robinson COG Life lrobinson@cglife.com
Maravai LifeSciences (NASDAQ:MRVI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Maravai LifeSciences (NASDAQ:MRVI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024